| ²é¿´: 565 | »Ø¸´: 2 | ||
| µ±Ç°Ö»ÏÔʾÂú×ãÖ¸¶¨Ìõ¼þµÄ»ØÌû£¬µã»÷ÕâÀï²é¿´±¾»°ÌâµÄËùÓлØÌû | ||
yolanda1234½ð³æ (СÓÐÃûÆø)
|
[ÇóÖú]
ÇóÃÀ¹úµÄÒ»¸öÐÂҩרÀû
|
|
|
±¾ÈËÔÚÉúÎï¹ÈÖп´µ½Ò»ÔòÏûÏ¢£¬ÔÎÄΪ£º2013Äê3ÔÂ5ÈÕѶ /ÉúÎï¹ÈBIOON/ --ÎäÌTakeda£©ÓëÃÀ¹úÉúÎï¼¼Êõ¹«Ë¾Resolve Therapeutics´ï³ÉÁ˺Ï×÷»ï°é¹ØÏµ£¬¹²Í¬¿ª·¢»¯ºÏÎÓÃÓÚÖÎÁƺì°ßÀÇ´¯¼°ÆäËû×ÔÉíÃâÒßÐÔ¼²²¡¡£Ïȵ¼»¯ºÏÎïRSLV-132ÊÇÒ»ÖÖºËøFcÈںϵ°°×£¬Äܹ»½µ½â²¢Çå³ýº¬ÓÐ×ÔÉí¿¹ÌåµÄÃâÒ߸´ºÏÎ˫·½½«ÔÚ½ñÄêÍíЩʱÆÚÆô¶¯¸Ã»¯ºÏÎïµÄÁÙ´²¿ª·¢¡£´ËÍ⣬»¹ÓÐÊýÖÖ»¯ºÏÎï´¦ÓÚÁÙ´²Ç°µÄ¸ÅÄîÑéÖ¤½×¶Î¡££¨ÉúÎï¹Èbioon.com£© ÏêϸӢÎı¨µÀ£º The lead compound, RSLV-132, is a nuclease Fc fusion protein that degrades and eliminates autoantibody-containing immune complexes, which are thought to be the most proximal pathophysiological trigger of lupus. It will begin clinical development later this year. Additional Resolve clinical candidates are in the pre-clinical proof-of-concept stage. Resolve will conduct all development work under the collaboration until completion of the first RSLV-132 Phase 1b/2a trial in lupus patients. Takeda has the exclusive option to license the lead compound and all other compounds from the Resolve platform upon the completion of the Phase 1b/2a trial. Upon exercise of its option, Takeda would assume lead responsibility for worldwide development and commercialization of the Resolve products. Under the terms of the agreement, Takeda will help fund continued development of RSLV-132 through an initial payment of US$8 million to Resolve in fiscal 2012. Upon exercise of its option, Takeda would pay Resolve an option exercise fee, plus the potential for additional development milestones totaling US$247 million. Furthermore Resolve is eligible to receive royalties on product sales. ¹Ø¼ü´Ê£º ÎäÌï ºì°ßÀÇ´¯ ÇóÕâ¸öRSLV-132µÄרÀûÔÎÄ¡£¡£¡£¡£¡£¡£¡£ |
» ²ÂÄãϲ»¶
ÉúÎï×éÖ¯ÖÐÓÐÄ¿±ê·ÖÎöÎרÊôÐÔÔõô×ö
ÒѾÓÐ0È˻ظ´
[ÇóÖú] Á÷ʽËÀ»îȾ & µ¥Ï¸°ûÃÅ¿ØÉèÖñ»ÖÊÒÉ£¬ÈçºÎÓÅ»¯²¢½âÊÍ£¿
ÒѾÓÐ1È˻ظ´
Ò©ÎïѧÂÛÎÄÈóÉ«/·ÒëÔõôÊÕ·Ñ?
ÒѾÓÐ255È˻ظ´
µ°°×Îȶ¨ÐÔʵÑéÓ빦ÄÜʵÑé²»Ò»ÖÂ
ÒѾÓÐ11È˻ظ´
µÚ4ÄêÁË£¬ÂíÉÏ40ÁË£¬¿ÉÄÜÎÒÓë¹ú»ùȷʵÎÞÔµ°É¡£¡£¡£
ÒѾÓÐ12È˻ظ´
26ÓÐûÓÐÀÏʦÏëÊÕ×ö¶¨Á¿Ò©ÀíµÄѧÉú°¡
ÒѾÓÐ3È˻ظ´
2026ÄêÉ격ҩѧרҵ
ÒѾÓÐ1È˻ظ´
26¿¼²©ÉêÇë ѧorר
ÒѾÓÐ15È˻ظ´
ҩѧר˶É격
ÒѾÓÐ3È˻ظ´
» ±¾Ö÷ÌâÏà¹Ø¼ÛÖµÌùÍÆ¼ö£¬¶ÔÄúͬÑùÓаïÖú:
ÃÀ¹úרÀûÖÐÔõôÕÒ²»µ½½á¹¹Ê½£¿Çó´óÏÀÖ¸µã£¡
ÒѾÓÐ9È˻ظ´
רÀûÎÊÌ⣬Çó¿ÆÆÕ£¡
ÒѾÓÐ4È˻ظ´
ÔÚUS Orange Book Óöµ½µÄһЩÎÊÌâ
ÒѾÓÐ4È˻ظ´
ÃÀ¹úרÀû¶àÉÙÄêµ½ÆÚ
ÒѾÓÐ7È˻ظ´
ÕâÑùµÄרÀû×å±£»¤£¬ÈÃÎÒÃÇ»¹ÄÜ·ÂÖÆÊ²Ã´ÄØ
ÒѾÓÐ11È˻ظ´
Ò»¸ö»¯Ñ§×¨ÀûÎÊÌ⣬Çë¸ßÊÖ½â´ð
ÒѾÓÐ22È˻ظ´
ÃÀ¹úרÀûÈçºÎ²é¶ÔÓ¦µÄÖйúרÀû
ÒѾÓÐ8È˻ظ´
ÃÀ¹úÊ®´óרÀûÒ©Ö®éä
ÒѾÓÐ20È˻ظ´
ÖÐÒ©Ò»ÀàÐÂÒ©Ñз¢ÖÐËùÓöµ½µÄרÀû±£»¤ÎÊÌâ
ÒѾÓÐ10È˻ظ´
×ªÔØ£ºÊ®´ó¡°ÖذõÕ¨µ¯¡±¼¶Ò©Æ·ÃæÁÙ¡°×¨ÀûÐüÑ¡±
ÒѾÓÐ15È˻ظ´
½»Á÷һϣ¬¹ØÓÚÒ©ÎïרÀû¹ýÆÚµÄʱ¼äÎÊÌâ¡£
ÒѾÓÐ8È˻ظ´
¡¾ÇóÖú¡¿ÃÀ¹úҩƷרÀûÑо¿Ö¸ÄÏ
ÒѾÓÐ8È˻ظ´
¡¾ÇóÖú¡¿×¨ÀûÏà¹ØÎÊÌâ
ÒѾÓÐ10È˻ظ´
¡¾ÇóÖú¡¿×¨ÀûµÄ³£Ê¶ÎÊÌâ
ÒѾÓÐ10È˻ظ´
¡¾ÌÖÂÛ¡¿ÊìϤרÀûµÄ³æÓÑÇë½ø
ÒѾÓÐ6È˻ظ´
¡¾ÇóÖú¡¿ÈçºÎ²éѯһÐÂÒ©ÓÐÎÞ»¯ºÏÎïרÀû°¡£¿
ÒѾÓÐ15È˻ظ´
¡¾ÇóÖú¡¿ÐÂÒ©ºÍ·ÂÒ©µÄÇø±ð£¿
ÒѾÓÐ7È˻ظ´
¡¾ÇóÖú¡¿Ò»¸ö¹ØÓÚ¹ú¼ÊרÀûµÄÎÊÌâ
ÒѾÓÐ10È˻ظ´
¡¾ÇóÖú¡¿ÐÂÒ©É걨רÀû²ßÂÔ
ÒѾÓÐ8È˻ظ´
¡¾ÇóÖú¡¿ÇóÎÊÔõô²éij¸öÒ©ÎïרÀûÊÇ·ñµ½ÆÚ£¿
ÒѾÓÐ18È˻ظ´

jinlong3820
½ð³æ (ÖøÃûдÊÖ)
- Ó¦Öú: 5 (Ó×¶ùÔ°)
- ½ð±Ò: 2775.5
- É¢½ð: 66
- ºì»¨: 2
- Ìû×Ó: 1191
- ÔÚÏß: 175.2Сʱ
- ³æºÅ: 786688
- ×¢²á: 2009-06-04
- ÐÔ±ð: GG
- רҵ: ÉúÎﻯѧ

3Â¥2013-03-09 10:37:16
wjswift
ÖÁ×ðľ³æ (Ö°Òµ×÷¼Ò)
¿´ÎÄÏ×£¬×öʵÑé......
- DRDEPI: 1
- Ó¦Öú: 33 (СѧÉú)
- ¹ó±ö: 1.131
- ½ð±Ò: 15527.4
- É¢½ð: 20
- ºì»¨: 33
- Ìû×Ó: 3911
- ÔÚÏß: 694.8Сʱ
- ³æºÅ: 112270
- ×¢²á: 2005-11-21
¡¾´ð°¸¡¿Ó¦Öú»ØÌû
¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï
¸Ðл²ÎÓ룬ӦÖúÖ¸Êý +1
yolanda1234: ½ð±Ò+30, ¡ï¡ï¡ï¡ï¡ï×î¼Ñ´ð°¸, ÆäʵÊÇÎÒÏëÖªµÀÕâ¸ö¿ìѶÊÇ·ñÊÇÕæµÄ£¬Ð»Ð»Ä㣬Õâô¿ì¾Í¸øÎһظ´ÁË¡£»¹ÓÐÎÊÌâÏëÎÊÂ¥Ö÷Ŷ¡£Õâ¸öÒ©£¬Èç¹ûͶÈëÊг¡»¹Òª¶à¾Ã£¿ 2013-03-08 17:17:08
³ÕÒÄ×ÓÆ¤: ½ð±Ò+2, лл½»Á÷£¬»¶Ó³£À´Å¶¡£ 2013-03-09 08:01:27
¸Ðл²ÎÓ룬ӦÖúÖ¸Êý +1
yolanda1234: ½ð±Ò+30, ¡ï¡ï¡ï¡ï¡ï×î¼Ñ´ð°¸, ÆäʵÊÇÎÒÏëÖªµÀÕâ¸ö¿ìѶÊÇ·ñÊÇÕæµÄ£¬Ð»Ð»Ä㣬Õâô¿ì¾Í¸øÎһظ´ÁË¡£»¹ÓÐÎÊÌâÏëÎÊÂ¥Ö÷Ŷ¡£Õâ¸öÒ©£¬Èç¹ûͶÈëÊг¡»¹Òª¶à¾Ã£¿ 2013-03-08 17:17:08
³ÕÒÄ×ÓÆ¤: ½ð±Ò+2, лл½»Á÷£¬»¶Ó³£À´Å¶¡£ 2013-03-09 08:01:27
|
US20120225066 CN102770533 http://1000eb.com/gksl ¸Ð¾õlzÇóÖúµÄ¶«Î÷ºÍÌîµÄרҵ²»´î°¡£¬ÕæÊÇÉæÁԹ㷺¡£¡£¡£ |

2Â¥2013-03-08 11:52:38













»Ø¸´´ËÂ¥